Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
    • Sjögren’s Disease
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Calcium Pyrophosphate Deposition Disease: The Great Mimic

Bryn Nelson, PhD  |  Issue: July 2025  |  July 9, 2025

Luckily, doctors have some therapeutic options for alleviating the symptoms. “We take the disease that’s most similar, and we borrow all the drugs,” Dr. Rosenthal says. “So pseudogout is treated almost exactly like gout.”

If only one or two joints are affected, Dr. Bettendorf says a localized treatment of injected corticosteroids can calm down the inflammation. “We can give somebody pretty quick relief with that and it’s pretty low risk to the patient,” she says. Non-steroidal anti-inflammatory drugs (NSAIDs) are another option, although a high-dose course may be less ideal for older patients with decreased kidney function. If the disease is caught early enough, the experts agree that colchicine can be particularly helpful.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Despite differences between the calcium pyrophosphate crystals and the uric acid crystals involved in gout, research suggests they use the same main pathways to induce inflammation. Those pathways involve the production of pro-inflammatory interleukin 1 (IL-1) and IL-6 cytokines, which help regulate the immune response. For that reason, some doctors have treated pseudogout that doesn’t respond to other medications with IL-1 beta antagonists, such as anakinra.

Dr. Bose

Other doctors, such as Nilanjana Bose, MD, MBA, a rheumatologist at Lonestar Rheumatology, Houston, emphasize that clinical data still haven’t provided clear direction on what to do when conventional treatments fail. “There are some recommended options, but I think these are all conjectural,” she says. “So I think there’s definitely a scope for how we can better treat these patients, especially those who are resistant to initial treatment and who continue to flare.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Although some gout treatments can reduce the levels of circulating uric acid and thus eliminate existing monosodium urate crystals, the same intervention isn’t possible for CPPD—at least not yet.4 “I think that we’re getting closer to being able to reduce pyrophosphate and halt crystal formation, which I think will be much better than just treating the inflammation as the crystals accumulate with age,” Dr. Rosenthal says.

Even if untreated, pseudogout generally goes away in seven to 10 days. “If my medication is posing undue risk to the patient, it may make sense to treat them with a pain medication and let them ride it out,” Dr. Bettendorf says.

She cautions that low-grade fevers and systemic malaise, potential symptoms of acute CPPD, could also warn of a septic joint, which is a medical emergency. “If we’re seeing those systemic symptoms, in most situations, especially if they don’t have a prior known diagnosis of CPPD arthritis, we really do need the joint tap or arthrocentesis because we need that fluid from the joint to rule out infection and other things,” Dr. Bettendorf says.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline ArthritisOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:arthrocentesiscalcium pyrophosphate deposition diseasechondrocalcinosisColchicineCorticosteroidscrystal arthritisGoutGout Resource CenterinflammationOsteoarthritispseudogoutRheumatoid arthritis

Related Articles

    New Insights into CPPD

    October 1, 2013

    Progress in research, outcomes, diagnosis, and treatment of calcium pyrophosphate dihydrate crystal deposition disease

    ACR Convergence graphic

    New Clinical Insights into the Pathogenesis, Diagnosis & Treatment of Calcium Pyrophosphate Arthritis

    December 17, 2020

    New diagnostic approaches combined with new evidence about pathogenesis are providing opportunities to help rheumatologists manage calcium pyrophosphate deposition disease.

    Case Report: CPPD Presenting as Pseudosepsis

    September 6, 2022

    Calcium pyrophosphate crystal deposition disease (CPPD) is an arthritis caused by the accumulation of calcium pyrophosphate crystals. Despite a prevalence of 4–7% among the adult population in Europe and the U.S., it has remained a relatively under-recognized disease owing to its many clinical presentations.1 CPPD may cause an acute mono/oligoarthritis, which may mimic gout or…

    Pseudo-What? Exploring the Classification Criteria Development Process for CPPD

    December 12, 2022

    PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences